Toward designing human intervention studies to prevent osteoarthritis after knee injury: A report from an interdisciplinary OARSI 2023 workshop.

Autor:	Whittaker JL; Department of Physical Therapy, University of British Columbia, Vancouver, Canada.; Arthritis Research Canada, Vancouver, Canada., Kalsoum R; Department of Immunology and Inflammation, Imperial College London, London, UK., Bilzon J; Department for Health, University of Bath, Bath, UK.; Centre for Sport, Exercise and Osteoarthritis Research Versus Arthritis, UK., Conaghan PG; Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, UK.; NIHR Leeds Biomedical Research Centre, Leeds, UK., Crossley K; La Trobe Sport and Exercise Medicine Research Centre, School of Allied Health, Human Services and Sport, La Trobe University, Melbourne, Australia., Dodge GR; Department of Orthopaedic Surgery, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.; Mechano Therapeutics LLC, Philadelphia, PA, USA., Getgood A; Division of Orthopedic Surgery, Bone and Joint Institute, Fowler Kennedy Sport Medicine Clinic, Schulich School of Medicine and Dentistry, University of Western Ontario, London, ON, Canada., Li X; Program of Advanced Musculoskeletal Imaging (PAMI), Cleveland Clinic, OH, USA.; Department of Biomedical Engineering, Lerner Research Institute, Cleveland Clinic, OH, USA., Losina E; Department of Orthopedic Surgery, Brigham and Women's Hospital, Boston, USA.; Department of Orthopedic Surgery, Harvard Medical School, Boston, USA., Mason DJ; Biomechanics and Bioengineering Research Centre Versus Arthritis, School of Biosciences, Cardiff University, Cardiff, UK., Pietrosimone B; Department of Exercise and Sport Science, University of North Carolina, USA., Risberg MA; Norwegian School Sport Sciences, Oslo, Norway.; Division of Orthopedic Surgery, Oslo University Hospital, Oslo, Norway., Roemer F; Department of Radiology, Universitätsklinikum Erlangen & Friedrich- Alexander-Universität (FAU) Erlangen-Nürnberg, Erlangen, Germany.; Chobanian & Avedisian School of Medicine, Boston University, Boston, MA, USA., Felson D; Section of Rheumatology, Boston University Chobanian & Avedisian School of Medicine, Boston, MA, USA., Culvenor AG; La Trobe Sport and Exercise Medicine Research Centre, School of Allied Health, Human Services and Sport, La Trobe University, Melbourne, Australia., Meuffels D; Orthopedic and Sport Medicine Department, Erasmus MC, University Medical Center Rotterdam, Rotterdam, the Netherlands., Gerwin N; Novartis BioMedical Research, Basel, Switzerland., Simon LS; SDG LLC, Cambridge, MA, USA., Lohmander LS; Department of Clinical Sciences Lund, Orthopaedics, Lund University, Lund, Sweden., Englund M; Department of Clinical Sciences Lund, Orthopaedics, Clinical Epidemiology Unit, Lund University, Lund, Sweden., Watt FE; Department of Immunology and Inflammation, Imperial College London, London, UK.; Centre for Osteoarthritis Pathogenesis Versus Arthritis, Kennedy Institute of Rheumatology, University of Oxford, UK.
Jazyk:	angličtina
Zdroj:	Osteoarthritis and cartilage open [Osteoarthr Cartil Open] 2024 Feb 23; Vol. 6 (2), pp. 100449. Date of Electronic Publication: 2024 Feb 23 (Print Publication: 2024).
DOI:	10.1016/j.ocarto.2024.100449
Abstrakt:	Objective: The global impact of osteoarthritis is growing. Currently no disease modifying osteoarthritis drugs/therapies exist, increasing the need for preventative strategies. Knee injuries have a high prevalence, distinct onset, and strong independent association with post-traumatic osteoarthritis (PTOA). Numerous groups are embarking upon research that will culminate in clinical trials to assess the effect of interventions to prevent knee PTOA despite challenges and lack of consensus about trial design in this population. Our objectives were to improve awareness of knee PTOA prevention trial design and discuss state-of-the art methods to address the unique opportunities and challenges of these studies. Design: An international interdisciplinary group developed a workshop, hosted at the 2023 Osteoarthritis Research Society International Congress. Here we summarize the workshop content and outputs, with the goal of moving the field of PTOA prevention trial design forward. Results: Workshop highlights included discussions about target population (considering risk, homogeneity, and possibility of modifying osteoarthritis outcome); target treatment (considering delivery, timing, feasibility and effectiveness); comparators (usual care, placebo), and primary symptomatic outcomes considering surrogates and the importance of knee function and symptoms other than pain to this population. Conclusions: Opportunities to test multimodal PTOA prevention interventions across preclinical models and clinical trials exist. As improving symptomatic outcomes aligns with patient and regulator priorities, co-primary symptomatic (single or aggregate/multidimensional outcome considering function and symptoms beyond pain) and structural/physiological outcomes may be appropriate for these trials. To ensure PTOA prevention trials are relevant and acceptable to all stakeholders, future research should address critical knowledge gaps and challenges. Competing Interests: JW is a senior editor with the Journal of Orthopaedic and Sports Physical Therapy and associate editor with the British Journal of Sports Medicine. AC is an associate editor of British Journal of Sports Medicine and Osteoarthritis and Cartilage. FW is an associate editor of Osteoarthritis & Cartilage. In the last 3 years she has received consulting fees from Pfizer. FW is chair of the PARIS Trial Oversight Committee (unremunerated). FW is Co-lead, UK NIHR Translational Research Collaboration, Common MSK Conditions workstream (unremunerated). FR is shareholder of Boston Imaging Core Lab (BICL), LLC. and consultant to Grünenthal. He is Editor in Chief of Osteoarthritis Imaging and Associate Editor of Radiology. ME has received consulting fees from Cellcolabs AB. NG is an employee and shareholder of Novartis Pharma AG. DJM has patents granted for the use of drugs to prevent PTOA, has received research funding from Orphelion and tested drugs supplied by Orphelion and Novartis. MAR is a Scientific Advisory Board member for Centre for Sport, Exercise & Osteoarthritis Research Versus Arthritis and a Board member of a non-profit Hospital in Oslo; Norway: Lovisenberg Rehabilitering. PC has received consulting fees from AbbVie, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, Galapagos, Genascence, GlaxoSmithKline, Janssen, Levicept, Novartis, Pfizer, Stryker and UCB. GD has received consulting fees from Sanofi and Pacira and is owner/shareholder of Mechano Therapeutics LLC. AG has received consulting fees from Smith and Nephew and owns shares/stock in Precison OS, Osteosys Robotics and LinkX Robotics. SL has received consulting fees from Joint Academy and is member clinical trial DSMB, Astra Zeneca. EL is on the OARSI board of directors and is the deputy editor of The Journal of Bone and Joint Surgery. (© 2024 The Authors.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu